

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



20 June 2026

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

### **Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition**

---

This is to inform that Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or affiliates referred to as “Sun Pharma” or “Company”), has entered into an agreement pursuant to which Sun Pharma has agreed to acquire 100% outstanding shares of Innovcare Lifesciences Private Limited, a company based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products.

**Annexure A**, enclosed herewith, provides the particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Part A of Schedule III.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050

**Annexure A****Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Sl. No.	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	Innovcare Lifesciences Private Limited (“Innovcare”), a company duly incorporated under Companies Act, 2013, and having its registered office at Mumbai, Maharashtra, India, is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products.  The revenue from operations for FY 2025-26 was INR 94.06 crores.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No, the transaction is not a related party transaction and promoter / promoter group does not have any interest in the entity whose securities are being acquired.
c)	Industry to which the entity being acquired belongs	Pharmaceuticals and Healthcare
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Strategic investment to strengthen product portfolio of the Company
e)	Brief details of any governmental or regulatory approvals required for the acquisition	None
f)	Indicative time period for completion of the acquisition	On or before 31 July 2026
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h)	Cost of acquisition or the price at which the shares are acquired	Cash consideration aggregating ~Rs 271.2 Crores.

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050



i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	Agreement to acquire 100% outstanding shares.								
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Innovcare is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products.</p> <p>Innovcare was incorporated on 21 July 2014.</p> <p>The revenue from operations for previous three years is as follows,</p> <table border="1" data-bbox="837 804 1430 982"><thead><tr><th data-bbox="837 804 1081 873">FY</th><th data-bbox="1081 804 1430 873">Turnover (in INR Crores)</th></tr></thead><tbody><tr><td data-bbox="837 873 1081 909">2025-26</td><td data-bbox="1081 873 1430 909">94.06</td></tr><tr><td data-bbox="837 909 1081 945">2024-25</td><td data-bbox="1081 909 1430 945">86.09</td></tr><tr><td data-bbox="837 945 1081 982">2023-24</td><td data-bbox="1081 945 1430 982">80.93</td></tr></tbody></table> <p>Countries in which Innovcare has presence: India</p>	FY	Turnover (in INR Crores)	2025-26	94.06	2024-25	86.09	2023-24	80.93
FY	Turnover (in INR Crores)									
2025-26	94.06									
2024-25	86.09									
2023-24	80.93									